Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice

Neuropharmacology

Volumn 93, Issue , 2015, Pages 209-218

  Ren, Zhili ^a   Yang, Nan ^a   Ji, Chao ^a   Zheng, Ji ^a   Wang, Tao ^a   Liu, Yanyong ^a   Zuo, Pingping ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

5 (4 hydroxy 3 dimethoxybenzylidene) 2 thioxo 4 thiazolidinone; Mitochondrial dysfunction; MPP+; MPTP; Parkinson's disease

Indexed keywords

5 (4 HYDROXY 3 DIMETHOXYBENZYLIDENE) 2 THIOXO 4 THIAZOLIDINONE; ADENOSINE TRIPHOSPHATE; BENSERAZIDE PLUS LEVODOPA; PARKIN; RHODANINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-(4-HYDROXY-3,5-DIMETHYLBENZYLIDENE)THIAZOLIDINE-2,4-DIONE; BENZYLIDENE DERIVATIVE; LEVODOPA; MITOCHONDRIAL PROTEIN; NEUROPROTECTIVE AGENT; NEUROTOXIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOT2 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SYNTHESIS; IMMUNOBLOTTING; LOCOMOTION; MALE; MESENCEPHALON; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL; NERVE FIBER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OPTICAL DENSITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; MPTP POISONING; NEUROBLASTOMA; NEWBORN; PATHOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; TIME; ULTRASTRUCTURE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; BENZYLIDENE COMPOUNDS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; LEVODOPA; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MESENCEPHALON; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MPTP POISONING; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PSYCHOMOTOR PERFORMANCE; RHO GTP-BINDING PROTEINS; THIAZOLIDINEDIONES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84923625000     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.01.030     Document Type: Article

References (59)

1. H.N. Allbutt, and J.M. Henderson Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease J. Neurosci. Methods 159 2007 195 202
2. M.F. Beal Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease Park. Relat. Disord. 15 Suppl. 3 2009 S189 S194
3. N. Birsa, R. Norkett, N. Higgs, G. Lopez-Domenech, and J.T. Kittler Mitochondrial trafficking in neurons and the role of the Miro family of GTPase proteins Biochem. Soc. Trans. 41 2013 1525 1531
4. V. Bogaerts, J. Theuns, and C. van Broeckhoven Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes. Brain Behav. 7 2008 129 151
5. K.M. Bowling, Z. Huang, D. Xu, F. Ferdousy, C.D. Funderburk, N. Karnik, W. Neckameyer, and J.M. O'Donnell Direct binding of GTP cyclohydrolase and tyrosine hydroxylase: regulatory interactions between key enzymes in dopamine biosynthesis J. Biol. Chem. 283 2008 31449 31459
6. A.C. Calvo, A.L. Pey, A. Miranda-Vizuete, A.P. Doskeland, and A. Martinez Divergence in enzyme regulation between Caenorhabditis elegans and human tyrosine hydroxylase, the key enzyme in the synthesis of dopamine Biochem. J. 434 2011 133 141
7. V. Cavallucci, A. Nobili, and M. D'Amelio Emerging role of mitochondria dysfunction in the onset of neurodegenerative diseases J. Biol. Regul. Homeost. Agents 27 2013 1 9
8. Y. Chen, and Z.H. Sheng Kinesin-1-syntaphilin coupling mediates activity-dependent regulation of axonal mitochondrial transport J. Cell Biol. 202 2013 351 364
9. W.S. Choi, H.W. Kim, and Z. Xia Preparation of primary cultured dopaminergic neurons from mouse brain Methods Mol. Biol. 1018 2013 61 69
10. I.E. Clark, M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, J.H. Seol, S.J. Yoo, B.A. Hay, and M. Guo Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin Nature 441 2006 1162 1166
11. C. Cleren, L. Yang, B. Lorenzo, N.Y. Calingasan, A. Schomer, A. Sireci, E.J. Wille, and M.F. Beal Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism J. Neurochem. 104 2008 1613 1621
12. L.A. Cranwell-Bruce Drugs for Parkinson's disease Medsurg Nurs. 19 2010 347 349
13. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
14. I.P. de Castro, L.M. Martins, and S.H.Y. Loh Mitochondrial quality control and Parkinson's disease: a pathway unfolds Mol. Neurobiol. 43 2010 80 86
15. I.P. de Castro, L.M. Martins, and R. Tufi Mitochondrial quality control and neurological disease: an emerging connection Expert Rev. Mol. Med. 12 2010 e12
16. H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H. Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Arancio, J.X. Chen, and S.D. Yan Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease Nat. Med. 14 2008 1097 1105
17. H. Du, and S.S. Yan Mitochondrial medicine for neurodegenerative diseases Int. J. Biochem. Cell Biol. 42 2010 560 572
18. H.M. Gao, B. Liu, and J.S. Hong Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons J. Neurosci. 23 2003 6181 6187
19. K. Gaweda-Walerych, and C. Zekanowski Integrated pathways of parkin control over mitochondrial maintenance - relevance to Parkinson's disease pathogenesis Acta Neurobiol. Exp. (Wars) 73 2013 199 224
20. J.C. Greene, A.J. Whitworth, I. Kuo, L.A. Andrews, M.B. Feany, and L.J. Pallanck Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants Proc. Natl. Acad. Sci. U. S. A. 100 2003 4078 4083
21. X. Guo, G.T. Macleod, A. Wellington, F. Hu, S. Panchumarthi, M. Schoenfield, L. Marin, M.P. Charlton, H.L. Atwood, and K.E. Zinsmaier The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses Neuron 47 2005 379 393
22. E.C. Hirsch, P. Jenner, and S. Przedborski Pathogenesis of Parkinson's disease Mov. Disord. 28 2013 24 30
23. M.L. Jauslin, T. Meier, R.A. Smith, and M.P. Murphy Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants FASEB J. 17 2003 1972 1974
24. S. Kasparova, Z. Sumbalova, P. Bystricky, J. Kucharska, T. Liptaj, V. Mlynarik, and A. Gvozdjakova Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease Neurochem. Int. 48 2006 93 99
25. J.S. Kim-Han, J.A. Antenor-Dorsey, and K.L. O'Malley The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons J. Neurosci. 31 2011 7212 7221
26. T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno, and N. Shimizu Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 1998 605 608
27. E.A. Kozina, V.G. Khaindrava, V.S. Kudrin, V.G. Kucherianu, P.D. Klodt, E.V. Bocharov, K.S. Raevskii, G.N. Kryzhanovskii, and M.V. Ugriumov Experimental modeling of functional deficiency of the nigrostriatal dopaminergic system in mice Ross. Fiziol. Zh Im. I M. Sechenova 96 2010 270 282
28. J. Lee, J.H. Boo, and H. Ryu The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start? Adv. Drug Deliv. Rev. 61 2009 1316 1323
29. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
30. K.L. Lim, X.H. Ng, L.G. Grace, and T.P. Yao Mitochondrial dynamics and Parkinson's disease: focus on parkin Antioxid. Redox Signal 16 2012 935 949
31. J. Liu, and B.N. Ames Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease Nutr. Neurosci. 8 2005 67 89
32. J.R. Lovas, and X. Wang The meaning of mitochondrial movement to a neuron's life Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 1833 2013 184 194
33. L.J. Martin The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis therapy Biochim. Biophys. Acta 1802 2010 186 197
34. A. Misko, S. Jiang, I. Wegorzewska, J. Milbrandt, and R.H. Baloh Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex J. Neurosci. 30 2010 4232 4240
35. V.A. Morais, and B. De Strooper Mitochondria dysfunction and neurodegenerative disorders: cause or consequence J. Alzheimers Dis. 20 Suppl. 2 2010 S255 S263
36. G.M. Morotz, K.J. De Vos, A. Vagnoni, S. Ackerley, C.E. Shaw, and C.C. Miller Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria Hum. Mol. Genet. 21 2012 1979 1988
37. J. Park, Y. Kim, and J. Chung Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila Dis. Model Mech. 2 2009 336 340
38. J. Park, S.B. Lee, S. Lee, Y. Kim, S. Song, S. Kim, E. Bae, J. Kim, M. Shong, J.M. Kim, and J. Chung Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin Nature 441 2006 1157 1161
39. A. Rana, M. Rera, and D.W. Walker Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan Proc. Natl. Acad. Sci. 110 2013 8638 8643
40. V. Rangaraju, N. Calloway, and T.A. Ryan Activity-driven local ATP synthesis is required for synaptic function Cell 156 2014 825 835
41. R.L. Rawson, L. Yam, R.M. Weimer, E.G. Bend, E. Hartwieg, H.R. Horvitz, S.G. Clark, and E.M. Jorgensen Axons degenerate in the absence of mitochondria in C. elegans Curr. Biol. 24 2014 760 765
42. P.H. Reddy Mitochondrial medicine for aging and neurodegenerative diseases Neuromolecular Med. 10 2008 291 315
43. G.J. Russo, K. Louie, A. Wellington, G.T. Macleod, F. Hu, S. Panchumarthi, and K.E. Zinsmaier Drosophila Miro is required for both anterograde and retrograde axonal mitochondrial transport J. Neurosci. 29 2009 5443 5455
44. L.H. Sanders, J. McCoy, X. Hu, P.G. Mastroberardino, B.C. Dickinson, C.J. Chang, C.T. Chu, B. Van Houten, and J.T. Greenamyre Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease Neurobiol. Dis. 70 2014 214 223
45. W.M. Saxton, and P.J. Hollenbeck The axonal transport of mitochondria J. Cell Sci. 125 2012 2095 2104
46. A.H. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurology 7 2008 97 109
47. A. Schober Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP Cell Tissue Res. 318 2004 215 224
48. Z.-H. Sheng, and Q. Cai Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration Nat. Rev. Neurosci. 13 2012 77 93
49. Y. Shidara, and P.J. Hollenbeck Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia J. Neurosci. 30 2010 11369 11378
50. S.D. Skaper, G. Mercanti, and L. Facci Culture and characterization of rat mesencephalic dopaminergic neurons Methods Mol. Biol. 846 2012 91 101
51. S.R. Subramaniam, and M.F. Chesselet Mitochondrial dysfunction and oxidative stress in Parkinson's disease Prog. Neurobiol. 106-107 2013 17 32
52. R.H. Swerdlow The neurodegenerative mitochondriopathies J. Alzheimers Dis. 17 2009 737 751
53. T. Tomasic, and L.P. Masic Rhodanine as a privileged scaffold in drug discovery Curr. Med. Chem. 16 2009 1596 1629
54. P. Verstreken, T. Ohyama, and H.J. Bellen FM 1-43 labeling of synaptic vesicle pools at the Drosophila neuromuscular junction Methods Mol. Biol. 440 2008 349 369
55. H.L. Wang, A.H. Chou, A.S. Wu, S.Y. Chen, Y.H. Weng, Y.C. Kao, T.H. Yeh, P.J. Chu, and C.S. Lu PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons Biochim. Biophys. Acta 1812 2011 674 684
56. J. Wang, P.S. Green, and J.W. Simpkins Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells J. Neurochem. 77 2001 804 811
57. X. Wang, D. Winter, G. Ashrafi, J. Schlehe, L. Wong Yao, D. Selkoe, S. Rice, J. Steen, J. LaVoie Matthew, and L. Schwarz Thomas PINK1 and Parkin target miro for phosphorylation and degradation to arrest mitochondrial motility Cell 147 2011 893 906
58. B. Wildemann, and G. Bicker Nitric oxide and cyclic GMP induce vesicle release at Drosophila neuromuscular junction J. Neurobiol. 39 1999 337 346
59. W. Xie, O.W. Wan, and K.K. Chung New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease Biochim. Biophys. Acta 1802 2010 935 941